Development and Validation of a Deep Learning-Based Radiomic Signature for Predicting Treatment Response to Immunotherapy in Non-Small Cell Lung Cancer (NSCLC)


Authors : Rishi Reddy Kothinti

Volume/Issue : Volume 10 - 2025, Issue 2 - February

Google Scholar : https://tinyurl.com/4as7fyt3

Scribd : https://tinyurl.com/3f8u3995

DOI : https://doi.org/10.5281/zenodo.14936801

Abstract : Precision oncology faces an essential problem regarding creating stable biomarkers to forecast immunotherapy responses in non-small cell lung cancer (NSCLC). The research develops and validates deep learning-based radiomic signatures that provide accurate prediction potential regarding NSCLC immune therapy responses in patients. Radiomics methods were applied to CT and PET images for pre-treatment data extraction, producing heterogeneous tumor features. The researchers employed a deep learning model to analyze these features to develop to develop an effective radio mic signature to determine immunotherapy response. The model used NSCLC patients who received immunotherapy for model training and testing purposes using RECIST criteria and progression-free survival (PFS) for treatment response measurement. Researchers evaluated the radiomic signature performance by assessing accuracy and sensitivity alongside specificity and the Area under the receiver operating characteristic curve (AUC). A deep learning-based radiomic signature proved much more valuable than standard clinical and pathological measures as it effectively predicted which patients would profit from immunotherapy. The signature established generalizability through additional testing on different patient groups, which confirmed its reliability. The findings suggest that uniting deep learning technology with radio mics is a non-surgical approach for tailoring therapy plans, enhancing patient success, and reducing untreated cutting therapies in NSCLC.

Keywords : Non-Small Cell Lung Cancer, Immunotherapy, Deep Learning, Predictive Modeling, Personalized Medicine.

References :

  1. Schuster, M., Nechansky, A., & Kircheis, R. (2006). Cancer immunotherapy. Biotechnology Journal: Healthcare Nutrition Technology, 1(2), 138-147. https://doi.org/10.1002/biot.200500044
  2. Couzin-Frankel, J. (2013). Cancer immunotherapy. https://doi.org/10.1126/science.342.6165.1432
  3. Dillman, R. O. (2011). Cancer immunotherapy. Cancer biotherapy & radiopharmaceuticals, 26(1), 1-64. https://doi.org/10.1089/cbr.2010.0902
  4. Martin-Liberal, J., de Olza, M. O., Hierro, C., Gros, A., Rodon, J., & Tabernero, J. (2017). The expanding role of immunotherapy. Cancer treatment reviews, 54, 74-86. https://doi.org/10.1016/j.ctrv.2017.01.008
  5. Melief, C. J., Toes, R. M., Medema, J. P., Van Der Burg, S. H., Ossendorp, F., & Offringa, R. (2000). Strategies for immunotherapy of cancer. https://doi.org/10.1016/S0065-2776(00)75006-1
  6. Norman, P. S. (1980). An overview of immunotherapy: implications for the future. Journal of Allergy and Clinical Immunology, 65(2), 87-96. https://doi.org/10.1016/0091-6749(80)90191-8
  7. Baxevanis, C. N., Perez, S. A., & Papamichail, M. (2009). Cancer immunotherapy. Critical reviews in clinical laboratory sciences, 46(4), 167-189. https://doi.org/10.1080/10408360902937809
  8. Swartz, M. A., Hirosue, S., & Hubbell, J. A. (2012). Engineering approaches to immunotherapy. Science translational medicine, 4(148), 148rv9-148rv9. https://doi.org/10.1126/scitranslmed.3003763
  9. Taefehshokr, S., Parhizkar, A., Hayati, S., Mousapour, M., Mahmoudpour, A., Eleid, L., ... & Taefehshokr, N. (2022). Cancer immunotherapy: Challenges and limitations. Pathology-Research and Practice, 229, 153723. https://doi.org/10.1016/j.prp.2021.153723
  10. Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016). Coinhibitory pathways in immunotherapy for cancer. Annual review of immunology, 34(1), 539-573. https://doi.org/10.1146/annurev-immunol-032414-112049
  11. Ni, L., & Dong, C. (2017). New checkpoints in cancer immunotherapy. Immunological Reviews, 276(1), 52-65. https://doi.org/10.1111/imr.12524
  12. Wang, Y., Wang, M., Wu, H. X., & Xu, R. H. (2021). Advancing to the era of cancer immunotherapy. Cancer Communications, 41(9), 803-829. https://doi.org/10.1002/cac2.12178
  13. Cranmer, S. J., & Desmarais, B. A. (2017). What can we learn from predictive modeling? Political Analysis, 25(2), 145-166. https://doi.org/10.1017/pan.2017.3
  14. Junqué de Fortuny, E., Martens, D., & Provost, F. (2013). Predictive modeling with big data: is bigger better? Big data, 1(4), 215-226. https://doi.org/10.1089/big.2013.0037
  15. Brooks, L., & Perot, A. R. (1991). Exploring a predictive model. Psychology of Women Quarterly, 15(1), 31-47. https://doi.org/10.1016/j.pmrj.2014.08.941
  16. Brooks, L., & Perot, A. R. (1991). Exploring a predictive model. Psychology of Women Quarterly, 15(1), 31-47. https://doi.org/10.1111/j.1471-6402.1991.tb00476.x
  17. Baranyi, J., Pin, C., & Ross, T. (1999). Validating and comparing predictive models. International Journal of Food Microbiology, 48(3), 159-166. https://doi.org/10.1016/S0168-1605(99)00035-5
  18. Toma, M., & Wei, O. C. (2023). Predictive Modeling in Medicine. Encyclopedia, 3(2), 590-601. https://doi.org/10.3390/encyclopedia3020042
  19. Steen, P. M. (1994). Approaches to predictive modeling. The Annals of Thoracic Surgery, 58(6), 1836-1840. https://doi.org/10.1016/0003-4975(94)91723-X

Precision oncology faces an essential problem regarding creating stable biomarkers to forecast immunotherapy responses in non-small cell lung cancer (NSCLC). The research develops and validates deep learning-based radiomic signatures that provide accurate prediction potential regarding NSCLC immune therapy responses in patients. Radiomics methods were applied to CT and PET images for pre-treatment data extraction, producing heterogeneous tumor features. The researchers employed a deep learning model to analyze these features to develop to develop an effective radio mic signature to determine immunotherapy response. The model used NSCLC patients who received immunotherapy for model training and testing purposes using RECIST criteria and progression-free survival (PFS) for treatment response measurement. Researchers evaluated the radiomic signature performance by assessing accuracy and sensitivity alongside specificity and the Area under the receiver operating characteristic curve (AUC). A deep learning-based radiomic signature proved much more valuable than standard clinical and pathological measures as it effectively predicted which patients would profit from immunotherapy. The signature established generalizability through additional testing on different patient groups, which confirmed its reliability. The findings suggest that uniting deep learning technology with radio mics is a non-surgical approach for tailoring therapy plans, enhancing patient success, and reducing untreated cutting therapies in NSCLC.

Keywords : Non-Small Cell Lung Cancer, Immunotherapy, Deep Learning, Predictive Modeling, Personalized Medicine.

Video Explanation for Published paper

Never miss an update from Papermashup

Get notified about the latest tutorials and downloads.

Subscribe by Email

Get alerts directly into your inbox after each post and stay updated.
Subscribe
OR

Subscribe by RSS

Add our RSS to your feedreader to get regular updates from us.
Subscribe